{"filings":[{"id":1222636,"accession_number":"0001193125-26-279483","cik":1750284,"company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","form_type":"8-K","filed_at":"2026-06-23T20:19:56+00:00","items":["5.07"],"status":"ready","headline":"Olema shareholders elect directors, approve executive compensation, ratify auditor at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Four Class III directors elected: Bohen (67.5M for), Garland (66.2M), Larson (50.4M), Rappaport (67.3M).","Advisory vote on executive compensation approved: 68.0M for, 654K against, 15.9K abstain.","Ernst & Young ratified as independent auditor for FY2026: 75.8M for, 272K against, 52.5K abstain.","Broker non-votes of 7.5M on director and compensation proposals; none on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1120231231.522076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":649158,"accession_number":"0001193125-26-237832","cik":1750284,"company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","form_type":"8-K","filed_at":"2026-05-26T11:05:16+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Olema partners with Bayer for OP-3136 + darolutamide Phase 1b/2 in mCRPC; 36 patients, H2 2026 start","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Olema and Bayer will evaluate OP-3136 (KAT6 inhibitor) combined with darolutamide in ~36 mCRPC patients.","Phase 1b/2 study expected to initiate in second half of 2026; Bayer supplies darolutamide.","Olema retains full global commercial and marketing rights to OP-3136; clinical data and inventions jointly owned.","First clinical collaboration for OP-3136; builds on ongoing Phase 1/2 monotherapy and combination studies.","Olema to present initial Phase 1 OP-3136 monotherapy data at ASCO on May 30, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1120231231.522076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":584080,"accession_number":"0001193125-26-234848","cik":1750284,"company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","form_type":"8-K","filed_at":"2026-05-21T21:05:15+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Olema announces Phase 1 data for OP-3136: tumor shrinkage in 13/19 evaluable, no DLTs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["OP-3136 monotherapy well-tolerated up to 45 mg; no DLTs, no discontinuations due to TRAEs.","Among 19 evaluable patients, 13 showed tumor shrinkage; 2 confirmed + 1 unconfirmed partial response.","Most common TRAEs: dysgeusia (81% any grade), anemia (38%; 6% grade 3), neutropenia (34%; 28% grade 3).","Dose-proportional PK; at ≥6 mg steady-state concentrations exceeded preclinical efficacy targets.","Data presented at ASCO May 30; also presenting OPERA-02 Phase 3 trial-in-progress poster."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1120231231.522076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":22288,"accession_number":"0001193125-26-218142","cik":1750284,"company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","form_type":"8-K","filed_at":"2026-05-12T11:05:16+00:00","items":["2.02","9.01"],"status":"ready","headline":"Olema reports Q1 net loss $53.1M, cash $505.3M; Phase 3 OPERA-01 data due fall 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents, and marketable securities $505.3M as of March 31, 2026.","Net loss Q1 2026: $53.1M vs $30.4M Q1 2025, driven by higher R&D spend.","GAAP R&D expenses $49.2M (Q1 2026) vs $30.6M (Q1 2025); non-GAAP R&D $42.7M.","Top-line data from pivotal Phase 3 OPERA-01 (palazestrant monotherapy) expected fall 2026.","Initial Phase 1 data for OP-3136 to be presented at ASCO 2026."],"consensus_eps_estimate":-0.5394,"consensus_eps_actual":-0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1120231231.522076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95177,"accession_number":"0001193125-26-201751","cik":1750284,"company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Olema enters 7-year lease for ~38K sq ft corporate HQ in San Francisco","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease with KR Oyster Point II, LLC for 38,176 sq ft on 4th and 5th floors.","Base rent for Phase I (25,048 sq ft) is $12,361,188 over initial term.","Base rent for Phase II (13,128 sq ft) is $6,145,463.76 over initial term.","Initial term 7 years; one-time termination option at 60 months with $1,716,240.96 fee.","Cash security deposit of $427,546.80 required; move-in expected by December 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1120231231.522076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95176,"accession_number":"0001193125-26-191944","cik":1750284,"company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Olema Pharmaceuticals appoints Dr. Prakash Raman to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Raman appointed as Class II director effective April 28, 2026; term expires at 2028 annual meeting.","He brings over 20 years of biopharma experience; currently CEO of InduPro Therapeutics.","Received initial equity grants: option for 24,150 shares vesting monthly over 3 years, plus 2,911 shares vesting June 11, 2026.","Company highlights lead program palazestrant in two Phase 3 trials with OPERA-01 data expected fall 2026.","Board determined Dr. Raman is independent under Nasdaq rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1120231231.522076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108054,"accession_number":"0001193125-26-107154","cik":1750284,"company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Olema reports FY2025 net loss of $162.5M; cash $505.4M; OPERA-01 data fall 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 $46.1M, full year $162.5M; R&D expenses $43.2M and $157.7M respectively.","Cash and marketable securities $505.4M; raised $218.5M in public offering.","Phase 3 OPERA-01 top-line data expected fall 2026; Phase 1b/2 with Pfizer atirmociclib initiated.","OP-3136 initial clinical data expected Q2 2026; commercial launch prep for potential late 2027 approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1120231231.522076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108053,"accession_number":"0001193125-26-031792","cik":1750284,"company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","form_type":"8-K","filed_at":"2026-01-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Olema CFO/COO Kovacs departs Jan 30; CEO Bohen interim principal financial officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Shane Kovacs, COO and CFO, leaves Jan 30, 2026; not due to disagreement with company on financial operations.","Kovacs receives $621,283 lump sum: $562,640 salary, $23,443 prorated 2026 bonus, $35,200 COBRA.","Outstanding equity awards continue vesting while he consults through Aug 1, 2026.","CEO Sean Bohen, M.D., Ph.D., assumes interim principal financial officer role; search for permanent CFO launched."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1120231231.522076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108052,"accession_number":"0001193125-26-010507","cik":1750284,"company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Olema reports preliminary cash >$500M as of Dec 31, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary unaudited cash, equivalents and marketable securities exceed $500M (subject to year-end close).","No other financial results disclosed; annual 10-K filing pending.","Investor presentation posted on company website as of January 12, 2026.","Cash position provides runway for ongoing breast cancer pipeline development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1120231231.522076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124479,"accession_number":"0001193125-25-288343","cik":1750284,"company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","form_type":"8-K","filed_at":"2025-11-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Olema Pharmaceuticals announces $190M follow-on offering of 10M shares at $19.00","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 10,000,000 shares of common stock at $19.00 per share for gross proceeds of ~$190M.","Underwriters have a 30-day option to purchase up to 1,500,000 additional shares.","Closing expected on November 20, 2025, subject to customary conditions.","Underwriting agreement with TD Securities (USA) LLC as representative of the underwriters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1120231231.522076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124478,"accession_number":"0001193125-25-286206","cik":1750284,"company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","form_type":"8-K","filed_at":"2025-11-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Olema terminates ATM prospectus; no further sales until new filing","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Terminated ATM prospectus effective November 18, 2025.","Sales Agreement with TD Securities dated January 6, 2025 remains in force.","No further sales of common stock under the ATM until new prospectus filed.","Olema had not disclosed any sales under the prior ATM; no amounts given.","Move may indicate intent to file updated prospectus or reduce equity dilution."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1120231231.522076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124477,"accession_number":"0001193125-25-273228","cik":1750284,"company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Olema Q3 net loss $42.2M; cash $329M; initiates OPERA-02 Phase 3; Pfizer deal","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $42.2M for Q3 2025 vs $34.6M Q3 2024; cash, equivalents and securities $329.0M.","Initiated OPERA-02 Phase 3 trial of palazestrant + ribociclib in frontline ER+/HER2- MBC.","Clinical trial agreement with Pfizer to evaluate palazestrant + atirmociclib in Phase 1b/2.","Phase 1/2 of OP-3136 (KAT6 inhibitor) expanded into combos; initial results expected mid-2026.","Top-line data from OPERA-01 monotherapy Phase 3 expected in second half of 2026."],"consensus_eps_estimate":-0.4933,"consensus_eps_actual":-1.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1120231231.522076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124476,"accession_number":"0001193125-25-243765","cik":1750284,"company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","form_type":"8-K","filed_at":"2025-10-20T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Olema reports palazestrant + ribociclib Phase 1b/2 mPFS of 15.5 months in ER+/HER2- MBC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["As of July 8, 2025, 72 patients enrolled across 90 mg and 120 mg palazestrant dose cohorts with ribociclib 600 mg.","Median PFS for 120 mg cohort (56 patients) was 15.5 months for all; 12.2 months in prior CDK4/6i patients.","In prior CDK4/6i patients, mPFS was 9.2 months (ESR1 wild-type) and 13.8 months (ESR1 mutant tumors).","Combination well tolerated, no new safety signals, no drug-drug interactions, consistent with known profiles.","Data support ongoing Phase 3 OPERA-02 trial evaluating palazestrant + ribociclib in frontline MBC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1120231231.522076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141140,"accession_number":"0001750284-25-000007","cik":1750284,"company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Olema enters clinical trial agreement with Pfizer for palazestrant + atirmociclib phase 1b/2","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1b/2 study to evaluate safety and combinability of palazestrant plus Pfizer’s investigational CDK4 inhibitor atirmociclib in ER+/HER2- metastatic breast cancer.","Study planned for approximately 35 patients with initiation anticipated in H2 2025.","Results to inform potential Phase 3 pivotal trial in frontline metastatic setting.","Olema retains full global commercial and marketing rights to palazestrant; Pfizer supplies atirmociclib.","This is Olema’s second clinical trial agreement with Pfizer; prior agreement from Nov 2020 for palazestrant + palbociclib."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1120231231.522076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141139,"accession_number":"0000950170-25-106545","cik":1750284,"company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Olema Q2 net loss $43.8M, selects 90 mg palazestrant dose for Phase 3 trials, cash $361.9M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q2 net loss $43.8M vs $30.4M YoY; increase driven by $10M Aurigene milestone and higher R&D for late-stage trials.","Selected 90 mg once-daily palazestrant for OPERA-01 Part 2 and OPERA-02 frontline combo trial with ribociclib.","OPERA-01 top-line data expected H2 2026; OPERA-02 initiation on track for Q3 2025.","Cash, equivalents, and marketable securities $361.9M as of June 30, 2025.","Mature palazestrant+ribociclib Phase 1b/2 data to be presented at ESMO 2025; OP-3136 Phase 1 enrolling."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1120231231.522076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158942,"accession_number":"0000950170-25-086256","cik":1750284,"company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Olema shareholders elect three Class II directors, approve say-on-pay, ratify EY","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Cynthia Butitta: 44,675,129 for, 11,733,848 withheld; Cyrus Harmon: 43,838,514 for, 12,570,463 withheld; Graham Walmsley: 44,120,432 for, 12,288,545 withheld.","Advisory vote on executive compensation: 54,057,177 for, 2,297,482 against, 54,317 abstain; broker non-votes 6,361,695.","Ratification of Ernst & Young as auditor: 62,732,079 for, 24,064 against, 14,528 abstain; no broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1120231231.522076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158941,"accession_number":"0000950170-25-070291","cik":1750284,"company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Olema Q1 2025: $392.7M cash, net loss $30.4M; palazestrant combo mPFS 13.8 months","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents, and marketable securities of $392.7M at March 31, 2025; net loss $30.4M.","Updated mPFS from Phase 1b/2: 13.8 months (all patients) and 13.1 months (prior CDK4/6i) for palazestrant+ribociclib.","Phase 3 OPERA-01 top-line data expected in 2026; OPERA-02 in frontline breast cancer to start in 2025.","GAAP R&D expenses $30.6M in Q1 2025, up from $29.9M; non-GAAP R&D $27.3M excluding stock comp.","OP-3136 Phase 1 trial enrollment ongoing; preclinical data at AACR showed activity in ovarian, NSCLC, prostate."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1120231231.522076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177368,"accession_number":"0000950170-25-041186","cik":1750284,"company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","form_type":"8-K","filed_at":"2025-03-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Olema reports FY2024 net loss $129.5M; cash $434.1M; palazestrant Phase 3 on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 $33.6M, FY $129.5M vs. $26.8M and $96.7M in 2023; R&D expense $124.5M FY.","Cash, equivalents & marketable securities $434.1M at Dec 31, 2024, up from $250M private placement.","Phase 3 OPERA-01 monotherapy top-line data expected 2026; OPERA-02 combo trial with Novartis starts 2025.","Phase 1 trial of OP-3136 initiated in Q4 2024; patients currently enrolling.","Updated mPFS data for palazestrant + ribociclib presented at March 2025 TD Cowen; mature data pending."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1120231231.522076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177367,"accession_number":"0000950170-25-033073","cik":1750284,"company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","form_type":"8-K","filed_at":"2025-03-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Olema Pharmaceuticals posts investor presentation with no material new disclosures","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company made investor presentation available on its website on March 5, 2025.","Presentation title: 'Advancing medicines for breast cancer and beyond'.","No specific financial or clinical updates provided in the filing.","Presentation appears to be a standard corporate overview.","Confidence low due to lack of substantive details in exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1120231231.522076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177366,"accession_number":"0000950170-25-004563","cik":1750284,"company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Olema Pharmaceuticals makes investor presentation available; no specific facts disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company filed Form 8-K with investor presentation dated January 13, 2025.","Presentation content not provided; no new financial or clinical data reported.","No material updates on pipeline, earnings, or corporate events available from filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1120231231.522076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177365,"accession_number":"0001193125-25-004427","cik":1750284,"company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"Olema exchanges ~6.07M shares for pre-funded warrants with Bain, Paradigm, BVF","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered exchange agreements to swap 6,070,000 common shares for pre-funded warrants at $0.0001 exercise price.","Exchange expected to close Jan 13, 2025; post-close outstanding shares estimated at 68,333,065.","Warrants exercisable immediately; beneficial ownership capped at 9.99% (can be raised to 19.99% with notice).","Issuance exempt from registration under Securities Act Section 3(a)(9); not a registered offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1120231231.522076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194121,"accession_number":"0000950170-24-134759","cik":1750284,"company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","form_type":"8-K","filed_at":"2024-12-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Olema gets FDA IND clearance for OP-3136; palazestrant combo shows 73% 6-month PFS","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA cleared IND for KAT6 inhibitor OP-3136; Phase 1 to start early 2025.","Phase 1b/2 palazestrant + ribociclib: median PFS not reached at 12-month follow-up.","6-month PFS rate 73% overall, 81% in ESR1 mutant patients, 68% after prior CDK4/6i.","ORR 27% (10/37) in measurable disease; 76% CBR overall.","Combination well tolerated with no new safety signals; plans for Phase 3 OPERA-02 in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1120231231.522076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194120,"accession_number":"0000950170-24-131965","cik":1750284,"company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","form_type":"8-K","filed_at":"2024-12-02T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Olema Pharma enters Novartis collaboration for Phase 3 breast cancer trial and raises $250M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Collaboration with Novartis provides ribociclib supply for planned Phase 3 OPERA-02 trial of palazestrant in ER+/HER2- frontline advanced/metastatic breast cancer, initiation expected mid-2025.","$250M private placement: 19,928,875 shares at $9.08 and pre-funded warrants for 7,604,163 shares; gross proceeds ~$250M, closing expected Dec 4, 2024.","Novartis receives right of first negotiation on any sale of palazestrant or change of control; repayment obligation of up to ~$275M proportional to ribociclib supplied.","Proceeds to fund OPERA-02, Phase 1/2 OP-3136 study, ongoing Phase 3 OPERA-01 monotherapy trial; OPERA-01 topline data expected in 2026.","Investors include Adage Capital, Bain Capital Life Sciences, BVF, Driehaus, Janus Henderson, Paradigm, Wellington, Woodline, and a large investment manager."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1120231231.522076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194119,"accession_number":"0000950170-24-125384","cik":1750284,"company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Olema Pharma Q3 net loss $34.6M; cash $214.8M; OP-3136 IND on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2024 net loss $34.6M vs $21.5M in Q3 2023; GAAP R&D $33.2M (up from $19.5M).","Cash, equivalents, marketable securities $214.8M as of Sep 30, 2024; no revenue reported.","OPERA-01 Phase 3 palazestrant monotherapy enrolling; top-line readout expected 2026.","IND submission for KAT6 inhibitor OP-3136 expected before year-end; Phase 1 start early 2025.","Updated Phase 2 palazestrant + ribociclib data to be presented at SABCS December 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1120231231.522076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210433,"accession_number":"0000950170-24-109753","cik":1750284,"company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","form_type":"8-K","filed_at":"2024-09-27T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Olema targets IND for KAT6 drug OP-3136 in Q4 2024; Phase 1/2 starts 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Non-clinical data for OP-3136 (KAT6 inhibitor) to be presented at ENA symposium Oct 23-25, 2024.","IND submission for OP-3136 anticipated in Q4 2024.","Phase 1/2 clinical study for OP-3136 expected to begin in 2025.","Potential Phase 3 trial OPERA-02 (palazestrant + ribociclib) initiation planned for 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1120231231.522076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210432,"accession_number":"0000950170-24-091799","cik":1750284,"company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Olema Q2 net loss $30.4M; cash $239.1M; palazestrant combo shows 85% CBR","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q2 2024 was $30.4M vs $20.1M in Q2 2023, driven by increased R&D spending on late-stage trials.","Cash, cash equivalents and marketable securities of $239.1M as of June 30, 2024.","Interim Phase 1b/2 data for palazestrant + ribociclib showed 85% clinical benefit rate in 13 evaluable patients.","IND for KAT6 inhibitor OP-3136 expected to be filed with FDA in late 2024; pre-clinical data in Q4.","Plan to initiate Phase 1b/2 study of palazestrant + everolimus in Q3 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1120231231.522076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210431,"accession_number":"0000950170-24-080546","cik":1750284,"company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","form_type":"8-K","filed_at":"2024-07-02T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Olema Pharmaceuticals amends loan facility, ups potential borrowing to $100M, extends maturity to 2028","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Borrowing capacity increased from $50M to up to $100M with $25M immediately available.","Additional $25M available upon milestone: execution of first line pivotal Phase 3 trial of palazestrant with ribociclib.","Further $50M may be available at bank's discretion; maturity extended 11 months to July 1, 2028.","No funds drawn under the loan agreement to date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1120231231.522076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228763,"accession_number":"0000950170-24-073749","cik":1750284,"company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Olema annual meeting results: directors elected, compensation approved, auditor ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Ian Clark elected with 33,874,399 for; Sandra Horning 40,102,098 for; Gorjan Hrustanovic 44,334,757 for.","Advisory say-on-pay vote approved: 45,174,223 for, 787,068 against, 8,069 abstain, 2,425,736 broker non-votes.","Ratification of Ernst & Young as independent auditor for FY2024 passed: 48,366,695 for, 19,160 against, 9,241 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1120231231.522076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228762,"accession_number":"0000950170-24-060031","cik":1750284,"company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Olema reports interim Phase 1b/2 data: palazestrant + ribociclib shows 85% CBR in ER+/HER2- mBC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Combination well tolerated in 50 patients; no new safety signals and no clinically meaningful drug-drug interaction.","Clinical benefit rate of 85% (11/13) overall; 83% in ESR1-mutant, 86% in wild-type, 83% in prior CDK4/6i patients.","Partial responses observed in 5 of 23 evaluable patients (2 confirmed, 3 unconfirmed); 66% remain on treatment.","Study fully enrolled at 60 patients; data support continued development for first-line ER+/HER2- advanced breast cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1120231231.522076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228761,"accession_number":"0000950170-24-055630","cik":1750284,"company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Olema reports Q1 net loss of $31.0M; cash $249M; enrollment complete in two palazestrant combo studies","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $31.0M for Q1 2024 vs $28.3M a year ago; cash & equivalents $249.0M.","GAAP R&D expenses $29.9M, including $5.0M milestone to Aurigene for KAT6 program.","Completed enrollment in 60-patient Phase 1b/2 studies of palazestrant + ribociclib and + palbociclib.","New clinical data for palazestrant+ribociclib at ESMO Breast Cancer May 15-17; investor call May 15.","Expect IND for OP-3136 (KAT6 inhibitor) in late 2024; plan Phase 1b/2 palazestrant+everolimus in Q3 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1120231231.522076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247410,"accession_number":"0000950170-24-029221","cik":1750284,"company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","form_type":"8-K","filed_at":"2024-03-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Olema reports FY2023 net loss $96.7M, cash $261.8M; palazestrant Phase 3 underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and marketable securities $261.8M as of Dec 31, 2023; net loss $96.7M for FY2023 vs $104.8M in FY2022.","GAAP R&D expenses $86.1M in FY2023 (including $11.8M stock-based comp); non-GAAP R&D $74.4M.","Pivotal Phase 3 OPERA-01 monotherapy trial initiated Q4 2023; top-line results expected in 2026.","Phase 2 study of palazestrant + ribociclib (60 patients) fully enrolled; data at ESMO Breast Cancer May 2024.","KAT6 inhibitor OP-3136 nominated as development candidate; IND filing expected late 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1120231231.522076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247409,"accession_number":"0000950170-24-002741","cik":1750284,"company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Olema makes investor presentation available for JP Morgan Conference; no financial details disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation furnished as Exhibit 99.1, dated January 8, 2024.","No specific clinical, financial, or pipeline updates provided in the filed text.","Presentation is for the JP Morgan Healthcare Conference in January 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1120231231.522076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247408,"accession_number":"0000950170-24-002721","cik":1750284,"company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Olema nominates OP-3136, KAT6 inhibitor for breast cancer; IND submission targeted by end of 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["OP-3136 is an orally bioavailable, potent KAT6A/B-selective inhibitor for ER+ breast cancer.","Preclinical data show dose-dependent tumor regression alone and synergy with CDK4/6 or palazestrant.","IND-enabling studies initiated; goal to file IND with FDA by end of 2024.","Aurigene receives $5M milestone payment upon initiation of IND-enabling studies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1120231231.522076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247407,"accession_number":"0000950170-24-002543","cik":1750284,"company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","form_type":"8-K","filed_at":"2024-01-05T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Olema Pharmaceuticals enters $150M ATM equity offering with TD Cowen, terminates prior Oppenheimer ATM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enters ATM agreement with Cowen and Company (TD Cowen) to sell up to $150M of common stock at market prices.","TD Cowen will receive up to 3.0% commission on gross proceeds from any sales under the agreement.","Terminates prior ATM agreement with Oppenheimer & Co., under which no sales were made.","No obligation to sell any shares; ATM may be terminated at any time.","Proceeds expected for general corporate purposes; registration statement effective since May 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1120231231.522076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264862,"accession_number":"0000950170-23-068439","cik":1750284,"company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","form_type":"8-K","filed_at":"2023-12-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Olema furnishes investor presentation at SABCS; no specific data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Investor presentation dated December 6, 2023 made available on company website.","Presentation exhibited as Exhibit 99.1 but full content not included in filing text.","No financial results, clinical data updates, or guidance changes referenced in the 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1120231231.522076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264861,"accession_number":"0000950170-23-068277","cik":1750284,"company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","form_type":"8-K","filed_at":"2023-12-05T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Olema reports positive Phase 1b/2 combo data for palazestrant; Phase 3 OPERA-01 enrolling","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Palazestrant + ribociclib (19 patients) well-tolerated; no dose-limiting toxicities, no drug-drug interaction.","Palazestrant + palbociclib (46 patients): clinical benefit rate 46% overall, 60% in ESR1 mutant, 71% in CDK4/6-naïve.","OPERA-01 Phase 3 monotherapy trial initiated; first patient dosed November 2023; sites activated.","Company anticipates potential Phase 3 combo trial start with ribociclib as early as end 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1120231231.522076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264860,"accession_number":"0001558370-23-017991","cik":1750284,"company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Olema reports Q3 net loss $21.5M, cash $276.9M; OPERA-01 Phase 3 on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $21.5M vs $22.7M YoY; cash, equivalents and marketable securities $276.9M.","R&D expenses $19.5M GAAP ($16.7M non-GAAP) as Phase 3 palazestrant trial advances.","OPERA-01 Phase 3 monotherapy trial site activation ongoing, first patient expected Q4 2023.","New palazestrant combination data with CDK4/6 inhibitors to be presented at SABCS Dec 2023.","Appointed Scott Garland to board; completed financing up to $180M (equity + credit facility)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.66,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1120231231.522076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264859,"accession_number":"0001558370-23-016589","cik":1750284,"company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","form_type":"8-K","filed_at":"2023-10-23T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Olema reports Phase 2 palazestrant results: median PFS 4.6 mo in all patients; 7.2 mo in 2nd/3rd-line subset","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Palazestrant (OP-1250) median PFS of 4.6 months (CBR 40%) in 86 heavily pretreated metastatic ER+/HER2- breast cancer patients.","In ESR1-mutant patients (48% of ctDNA-assessed), median PFS 5.6 months, CBR 52%; in 2nd/3rd-line subset PFS 7.3 mo, CBR 59%.","Safety: well-tolerated at 120 mg; Grade 4 neutropenia in 6 patients (all prior CDK4/6i), managed with dose reduction/discontinuation.","Company plans to initiate OPERA-01, a Phase 3 pivotal monotherapy trial in 2nd/3rd-line metastatic breast cancer.","Results presented at ESMO 2023; Olema hosted investor call on Oct 23, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1120231231.522076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264856,"accession_number":"0001558370-23-016518","cik":1750284,"company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","form_type":"8-K/A","filed_at":"2023-10-18T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Olema appoints Scott Garland to board of directors with extensive launch experience","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Scott Garland appointed to Olema's Board as Class III director effective Oct 16, 2023.","Garland brings >30 years biopharma experience; former CEO of PACT Pharma and Portola.","He received initial equity grants: 21,520 shares (option) vesting over 3 years, and 14,347 shares (option) vesting by 2024 annual meeting.","Also receives annual cash retainer of $40,000 and additional $6,000 for Compensation Committee service.","Board cites his commercial expertise as crucial as palazestrant enters Phase 3."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1120231231.522076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264858,"accession_number":"0001558370-23-016473","cik":1750284,"company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","form_type":"8-K","filed_at":"2023-10-17T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Olema appoints Scott Garland to Board; brings commercial expertise for late-stage palazestrant development","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Scott Garland appointed to Board as Class III director effective Oct 16, 2023; term through 2026 annual meeting.","Received initial equity: options for 21,520 shares (3-year vest) and 14,347 shares (vests by 2024 annual meeting).","Annual cash retainer $40,000 plus $6,000 for Compensation Committee service; standard indemnification agreement.","Garland formerly CEO of Portola (led Andexxa launch and Alexion acquisition) and held senior roles at Exelixis, Genentech, Amgen.","Company highlights his commercial leadership as palazestrant advances to Phase 3 for breast cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1120231231.522076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264857,"accession_number":"0001558370-23-016301","cik":1750284,"company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","form_type":"8-K","filed_at":"2023-10-10T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Olema and Novartis expand Phase 1/2 combo study of palazestrant + ribociclib to ~60 patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment adds ~30 patients to dose expansion, increasing study size to about 60 total.","Phase 1b dose escalation completed; Phase 2 expansion at 120 mg palazestrant + 600 mg ribociclib.","Expanded dataset may support regulatory path for a first-line pivotal trial in ER+ breast cancer.","Collaboration originally signed July 2020; amended in January 2022 and now expanded again.","Olema (OLMA) and Novartis (NVS) partner on this combination trial."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1120231231.522076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282048,"accession_number":"0001558370-23-015422","cik":1750284,"company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","form_type":"8-K","filed_at":"2023-09-05T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Olema raises $130M equity, secures $50M credit facility from SVB","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement of 13,211,382 shares at $9.84/share raises ~$130M gross.","$50M Silicon Valley Bank credit facility; $25M available at close, $25M discretionary.","Proceeds to fund palazestrant (OP-1250) development and extend runway into 2027.","Lock-up on shares until Phase 1b/2 data release or Dec 31, 2023.","Investors include Paradigm BioCapital, Lightspeed, Deep Track, BVF, Cormorant, Vivo, Logos, Woodline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1120231231.522076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282047,"accession_number":"0001558370-23-013927","cik":1750284,"company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Olema reports Q2 net loss $20.1M; cash $167.4M; Phase 3 trial on track Q4 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $20.1M for Q2 2023, down from $32.9M in Q2 2022; R&D expenses $18.0M.","Cash, cash equivalents and marketable securities $167.4M as of June 30, 2023, funding operations into Q2 2025.","OPERA-01 pivotal Phase 3 trial of palazestrant (OP-1250) monotherapy to enroll first patient in Q4 2023.","Palazestrant Phase 2 monotherapy data as oral presentation at ESMO Congress October 22, 2023.","Interim Phase 1b/2 combination data with CDK4/6 inhibitors to be presented in Q4 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1120231231.522076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301131,"accession_number":"0001558370-23-011291","cik":1750284,"company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","form_type":"8-K","filed_at":"2023-06-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Olema holds annual meeting; stockholders elect three directors, approve say-on-pay, ratify E&Y auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Sean P. Bohen, Yi Larson, and Andrew Rappaport elected as Class III directors through 2026 with votes 23.5M, 18.0M, and 23.7M for respectively.","Advisory vote on executive compensation approved: 18.7M for, 1.9M against, 5.0M abstain, 5.8M broker non-votes.","Ratification of Ernst & Young as independent auditor for FY2023 approved: 30.9M for, 10k against, 540k abstain.","Broker non-votes of 5.8M shares present on director and compensation proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1120231231.522076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301130,"accession_number":"0001558370-23-009282","cik":1750284,"company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Olema reports Phase 1b/2 data for OP-1250 + palbociclib in ER+/HER2- mBC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Combination of OP-1250 (up to 120 mg) with palbociclib 125 mg was safe and well-tolerated in 29 patients, with no DDI.","No dose-related increases in adverse events; neutropenia consistent with palbociclib plus endocrine therapy profile.","Partial responses observed in 5 patients (1 confirmed, 4 unconfirmed); clinical benefit rate 42% (5/12 CBR-eligible).","59% of patients remain on treatment as of March 8, 2023 data cut-off; enrollment ongoing toward ~45 patients.","OP-1250 showed favorable PK: 8-day half-life, dose-proportional exposure, no effect on palbociclib levels."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1120231231.522076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301129,"accession_number":"0001558370-23-008811","cik":1750284,"company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Olema Pharma Q1 net loss $28.3M, cash $186M; Phase 3 trial of OP-1250 planned H2 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities of $186.0M as of March 31, 2023, expected to fund operations into 2025.","Net loss for Q1 2023 was $28.3M, compared to $23.0M in Q1 2022, with R&D expenses rising to $22.8M from $16.0M.","Company plans to initiate pivotal Phase 3 monotherapy trial of OP-1250 in second-line metastatic breast cancer in H2 2023.","Interim Phase 2 results of OP-1250 plus palbociclib to be presented at ESMO Breast Cancer on May 12, 2023.","Non-GAAP R&D expenses were $19.7M (excl. $3.1M SBC) vs $12.9M YoY; includes $2.8M restructuring charge."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1120231231.522076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321015,"accession_number":"0001558370-23-003473","cik":1750284,"company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","form_type":"8-K","filed_at":"2023-03-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Olema confirms no cash deposits or securities at Silicon Valley Bank","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company holds zero cash or securities at Silicon Valley Bank.","Disclosure issued March 10, 2023, amid SVB's collapse.","No exposure implies no impact on company liquidity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1120231231.522076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321014,"accession_number":"0001558370-23-003309","cik":1750284,"company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","form_type":"8-K","filed_at":"2023-03-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Olema reports FY2022 net loss of $104.8M, restructures to focus on OP-1250 Phase 3","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $104.8M for FY2022, vs $71.1M in FY2021.","Cash and securities $204.4M at Dec 31, 2022, expected to fund operations into 2025.","Workforce reduced by ~25% to focus on late-stage development of OP-1250; CBO leaving, CRO stepping down from role.","Initiating first pivotal Phase 3 trial of OP-1250 in 2H 2023 for ER+/HER2- metastatic breast cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1120231231.522076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339123,"accession_number":"0001558370-22-018762","cik":1750284,"company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","form_type":"8-K","filed_at":"2022-12-16T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Olema Pharmaceuticals amends bylaws to update stockholder nomination procedures","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Board approved amended and restated bylaws effective December 15, 2022.","Revisions address Rule 14a-19 universal proxy rules and update director nomination information requirements.","Updated provisions on conduct of stockholder meetings and setting date, time, place."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1120231231.522076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339122,"accession_number":"0001558370-22-016899","cik":1750284,"company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Olema Pharma Q3 net loss $22.7M; cash $222.6M; OP-1250 shows 41% tumor reduction","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $22.7M in Q3 2022 vs $17.7M in Q3 2021; R&D expenses $17.6M GAAP ($14.8M non-GAAP).","Cash, equivalents and marketable securities $222.6M at Sept 30, 2022; sufficient into H2 2024.","OP-1250 monotherapy: 41% of heavily pre-treated patients had tumor reduction; 6 partial responses; Phase 2 fully enrolled.","OP-1250 + palbociclib combo: dose escalation completed, Phase 2 expansion ongoing; no dose-limiting toxicities.","Phase 3 monotherapy study planned for mid-2023; FDA Fast Track granted for ER+/HER2- metastatic breast cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1120231231.522076,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-11-08T23:59:59+00:00|339122"}